Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMJGleeson Regulatory News (GLE)

Share Price Information for MJGleeson (GLE)

Share Price is delayed by 15 minutes
Get Live Data
248.50    3.50 (1.43%)
Bid:
249.00
Ask:
251.00
Spread: 2.00 (0.803%)
Market Cap: £144.97m
GLE Live PriceLast checked at - London Stock Exchange

Intraday MJGleeson Share Chart

Trading Update

9 Jul 2020 07:00

RNS Number : 4622S
MJ Gleeson PLC
09 July 2020
 

MJ Gleeson plc (GLE.L)

("Gleeson", "the Company" or "the business")

 

For immediate release

 

 

9 July 2020

 

Notice of Results & Trading Update

 

MJ Gleeson plc (GLE.L), the low-cost housebuilder and strategic land specialist, today provides an update for the year ended 30 June 2020 ("FY2020"). The Company will report its audited full year results on Monday, 14 September 2020.

 

Gleeson Homes

 

Gleeson Homes completed the sale of 1,072 homes during the year, a reduction of 29.9% compared with the previous year's total of 1,529.

 

However, the division has entered the new financial year ("FY2021") in a strong position with a forward order book standing at £145.3m on 1,033 plots (June 2019: £87.6m on 677 plots) and over 1,000 built or part-built homes.

 

Net daily reservations over the last four weeks have risen to more than 80% of pre Covid-19 levels with the majority reserved at prices higher than in January and February 2020.

 

Four new build sites were opened in the last two months of the year bringing the total build sites to 71. Of these sites, 65 are actively selling. The business plans to open more than 25 new sites during FY2021 year and expects to have at least 80 active build sites by the end of the period.

 

Current safe-working protocols are, as expected, having an impact on productivity and build rate. Build activity on sites is currently running at 60% of pre Covid-19 levels and is expected to reach 80% by September 2020.

 

The land pipeline of owned and conditionally purchased plots at 30 June 2020 increased by 1.7% compared to the prior year end, totaling 13,801 plots on 149 sites, of which 6,952 plots have been purchased subject to planning permission.

 

Gleeson Strategic Land

 

During the year Gleeson Strategic Land sold two land interests with the potential to deliver 195 plots for housing development.

 

The division's total portfolio comprises 68 sites, with the potential to deliver 23,314 plots, and 44 acres of commercial land. Of these, planning permission has been granted on 11 sites that have the potential to deliver 3,855 plots (June 2019: 9 sites, 2,929 plots).

 

Prior to Covid-19, the division was seeing strong interest in its consented sites. As the land market reopens this interest is returning, with enquiries from a broad range of housebuilders.

 

Group

 

The Group ended the year with cash balances of £76.8m including £60m drawn on the Company's committed bank facility (30 June 2019: £30.3m net cash). In addition, the Group has a £10m committed overdraft facility which is currently undrawn.

 

The majority of furloughed staff have returned to work, either to site or working from home, and the voluntary management pay cuts introduced in April were reversed on 1 July. No further use of the furlough scheme is anticipated after July.

 

The Board expects the results for FY2020 to be in line with revised market expectations.

 

 

James Thomson, Chief Executive Officer, commented:

 

"The impact of Covid-19 on the FY2020 results is as expected. What is pleasing is that the business has demonstrated its underlying resilience in the face of enormous challenges and we are starting the new financial year in a strong position."

 

"Gleeson Strategic Land's pipeline is strong and housebuilders are returning to the market to acquire much-needed consented land which remains in short supply."

 

"Buying a high-quality affordable Gleeson home remains substantially cheaper than renting - often poor quality - accommodation. With strong demand and reservation levels expected to soon recover to pre Covid-19 levels, our robust pipeline will enable us to open more sites than ever as we continue to deliver on our strategic plan of completing 2,000 homes p.a. in FY2022."

 

"We are confident that, if the current market improvement continues, the Group will see a rapid recovery in FY2021."

 

 

 

Enquiries:

 

 

 

MJ Gleeson plc

James Thomson

Stefan Allanson

 

Chief Executive Officer

Chief Financial Officer

01142 612900

Instinctif

Mark Garraway

Rosie Driscoll

 

07771 860938

07891 564641

N+1 Singer

Shaun Dobson

Rachel Hayes

020 7496 3000

Liberum

Neil Patel

Richard Bootle

 

020 3100 2222

 

 

This announcement is released by MJ Gleeson plc and contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. Upon the publication of this announcement, this information is considered to be in the public domain.

 

For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, this announcement is being made on behalf of the Company by Stefan Allanson, Chief Financial Officer.

 

LEI: 21380064K7N2W7FD6434

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTUPUAUMUPUGBR
Date   Source Headline
12th Feb 20254:14 pmRNSDirector/PDMR Shareholding
11th Feb 20257:00 amRNSResults for the half year ended 31 December 2024
7th Feb 202511:51 amRNSDirector/PDMR Shareholding
14th Jan 20257:00 amRNSTrading Update & Notice of Results
7th Jan 20254:28 pmRNSDirector/PDMR Shareholding
9th Dec 20244:59 pmRNSDirector/PDMR Shareholding
3rd Dec 20243:50 pmRNSDirector/PDMR Shareholding
26th Nov 20243:34 pmRNSDirector/PDMR Shareholding
15th Nov 20242:08 pmRNSResult of AGM
15th Nov 20247:00 amRNSAGM Trading Update
7th Nov 20242:44 pmRNSDirector/PDMR Shareholding
30th Oct 202410:42 amRNSDirector/PDMR Shareholding
21st Oct 20247:00 amRNSNotice of AGM
18th Oct 20244:24 pmRNSDirector/PDMR Shareholding
18th Oct 20244:19 pmRNSDirector/PDMR Shareholding
9th Oct 20244:27 pmRNSDirector/PDMR Shareholding
4th Oct 202410:18 amRNSDirector/PDMR Shareholding
30th Sep 20247:00 amRNSTotal Voting Rights
18th Sep 20247:00 amRNSAudited results for the year ended 30 June 2024
9th Sep 202410:18 amRNSDirector/PDMR Shareholding
30th Aug 20247:00 amRNSTotal Voting Rights
7th Aug 20249:41 amRNSDirector/PDMR Shareholding
31st Jul 20247:00 amRNSTotal Voting Rights
23rd Jul 20242:36 pmRNSDirector/PDMR Shareholding
23rd Jul 20241:53 pmRNSStandard form for notification of major holdings
11th Jul 20247:00 amRNSFY2024 Trading Update
8th Jul 20241:34 pmRNSDirector/PDMR Shareholding
8th Jul 20247:00 amRNSNotice of Trading Update
28th Jun 20247:00 amRNSTotal Voting Rights
6th Jun 20242:46 pmRNSDirector/PDMR Shareholding
31st May 20247:00 amRNSTotal Voting Rights
15th May 20247:00 amRNSAppointment of Joint Corporate Broker
9th May 20249:41 amRNSDirector/PDMR Shareholding
30th Apr 20247:00 amRNSTotal Voting Rights
8th Apr 20243:41 pmRNSDirector/PDMR Shareholding
3rd Apr 20244:28 pmRNSDirector/PDMR Shareholding
2nd Apr 20243:28 pmRNSDirector/PDMR Shareholding
28th Mar 20247:00 amRNSTotal Voting Rights
22nd Mar 20249:07 amRNSDirector/PDMR Shareholding
20th Mar 20241:45 pmRNSDirector/PDMR Shareholding
29th Feb 20247:00 amRNSTotal Voting Rights
26th Feb 20241:04 pmRNSDirector/PDMR Shareholding
15th Feb 20247:00 amRNSResults for the half year ended 31 December 2023
7th Feb 202411:34 amRNSDirector/PDMR Shareholding
31st Jan 20247:00 amRNSTotal Voting Rights
9th Jan 202410:50 amRNSDirector/PDMR Shareholding
9th Jan 20247:00 amRNSTrading Update & Notice of Results
29th Dec 20237:00 amRNSTotal Voting Rights
15th Dec 20232:49 pmRNSRe Directorate External Appointments
6th Dec 20234:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.